The re-emergence of influenza following the COVID-19 pandemic in Victoria, Australia, 2021 to 2022.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
09 2023
Historique:
medline: 18 9 2023
pubmed: 14 9 2023
entrez: 14 9 2023
Statut: ppublish

Résumé

BackgroundCOVID-19 pandemic mitigation measures, including travel restrictions, limited global circulation of influenza viruses. In Australia, travel bans for non-residents and quarantine requirements for returned travellers were eased in November 2021, providing pathways for influenza viruses to be re-introduced.AimWe aimed to describe the epidemiological and virological characteristics of the re-emergence of influenza in Victoria, Australia to inform public health interventions.MethodsFrom 1 November 2021 to 30 April 2022, we conducted an epidemiological study analysing case notification data from the Victorian Department of Health to describe case demographics, interviewed the first 200 cases to establish probable routes of virus reintroduction and examined phylogenetic and antigenic data to understand virus diversity and susceptibility to current vaccines.ResultsOverall, 1,598 notifications and 1,064 positive specimens were analysed. The majority of cases (61.4%) occurred in the 15-34 years age group. Interviews revealed a higher incidence of international travel exposure during the first month of case detections, and high levels of transmission in university residential colleges were associated with return to campus. Influenza A(H3N2) was the predominant subtype, with a single lineage predominating despite multiple importations.ConclusionEnhanced testing for respiratory viruses during the COVID-19 pandemic provided a more complete picture of influenza virus transmission compared with previous seasons. Returned international travellers were important drivers of influenza reemergence, as were young adults, a group whose role has previously been under-recognised in the establishment of seasonal influenza epidemics. Targeting interventions, including vaccination, to these groups could reduce future influenza transmission.

Identifiants

pubmed: 37707981
doi: 10.2807/1560-7917.ES.2023.28.37.2300118
pmc: PMC10687983
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Virol. 2021 Nov 23;95(24):e0126721
pubmed: 34586866
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Clin Infect Dis. 2020 Feb 14;70(5):850-858
pubmed: 30963180
J Clin Virol. 2015 Jul;68:43-8
pubmed: 26071334
Vaccine. 2020 Aug 10;38(36):5747-5758
pubmed: 32703747
Trop Med Infect Dis. 2019 Jan 11;4(1):
pubmed: 30641917
Lancet Reg Health West Pac. 2021 Dec;17:100297
pubmed: 34723232
BMC Infect Dis. 2021 Aug 13;21(1):810
pubmed: 34388979
Med J Aust. 2022 Jan 17;216(1):25-26
pubmed: 34773924
MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1494-1496
pubmed: 33056949
MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1712-1714
pubmed: 34882659
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
Epidemiol Infect. 2010 Nov;138(11):1531-41
pubmed: 20594381
Influenza Other Respir Viruses. 2014 Mar;8(2):194-200
pubmed: 24382379
Influenza Other Respir Viruses. 2023 Jan;17(1):e13072
pubmed: 36451293
Emerg Infect Dis. 2013 Jun;19(6):925-31
pubmed: 23735636
Epidemics. 2022 Mar;38:100549
pubmed: 35255398
PLoS One. 2010 Mar 04;5(3):e9548
pubmed: 20209058
PLoS Pathog. 2018 Jan 11;14(1):e1006780
pubmed: 29324895
Int J Infect Dis. 2022 Sep;122:1002-1004
pubmed: 35932966
Int J Infect Dis. 2021 May;106:199-207
pubmed: 33771668
J Open Source Softw. 2021;6(57):
pubmed: 34189396
BMC Infect Dis. 2018 Dec 12;18(1):647
pubmed: 30541479
Lancet Reg Health West Pac. 2023 Mar;32:100675
pubmed: 36694478
Curr Protoc Bioinformatics. 2020 Mar;69(1):e96
pubmed: 32162851
Euro Surveill. 2021 Mar;26(11):
pubmed: 33739256
Lancet Glob Health. 2019 Aug;7(8):e1031-e1045
pubmed: 31303294
J Virol. 2003 Aug;77(15):8418-25
pubmed: 12857911
N Engl J Med. 2001 Mar 22;344(12):889-96
pubmed: 11259722
Nat Commun. 2022 Mar 31;13(1):1721
pubmed: 35361789
PLoS Med. 2013 Oct;10(10):e1001527
pubmed: 24115913
Clin Infect Dis. 2023 Feb 8;76(3):e1328-e1334
pubmed: 35959938
Nat Hum Behav. 2020 Dec;4(12):1303-1312
pubmed: 33199859
Am J Transplant. 2020 Dec;20(12):3681-3685
pubmed: 33264506
Med J Aust. 2022 Jan 17;216(1):33-38
pubmed: 34549433

Auteurs

Catherine Ga Pendrey (CG)

WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia.
Communicable Diseases, Health Protection Branch, Public Health Division, Department of Health, Victoria, Melbourne, Australia.

Janet Strachan (J)

Communicable Diseases, Health Protection Branch, Public Health Division, Department of Health, Victoria, Melbourne, Australia.

Heidi Peck (H)

WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Ammar Aziz (A)

WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Jean Moselen (J)

WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Rob Moss (R)

School of Population and Global Health, University of Melbourne, Melbourne, Australia.

Md Rezanur Rahaman (MR)

National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia.

Ian G Barr (IG)

WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Department of Immunology and Microbiology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Kanta Subbarao (K)

WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Department of Immunology and Microbiology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Sheena G Sullivan (SG)

WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Communicable Diseases, Health Protection Branch, Public Health Division, Department of Health, Victoria, Melbourne, Australia.
Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH